[PDF][PDF] Methotrexate in rheumatoid arthritis
J Œwierkot, J Szechiñski - Pharmacological reports, 2006 - Citeseer
A variety of disease-modifying antirheumatic drugs (DMARDs) are available to control the
clinical activity of rheumatoid arthritis (RA). Methotrexate (MTX), an analogue of folic acid and …
clinical activity of rheumatoid arthritis (RA). Methotrexate (MTX), an analogue of folic acid and …
[HTML][HTML] Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis
…, L Szczepański, J Szechiński… - … England Journal of …, 2004 - Mass Medical Soc
Background An open-label study indicated that selective depletion of B cells with the use of
rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To …
rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To …
Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an …
…, J Szechinski, K Pavelka, J Bröll… - Arthritis & …, 2006 - Wiley Online Library
Objective To establish the safety and efficacy of repeat infusions of tocilizumab (previously
known as MRA), a humanized anti–interleukin‐6 (IL‐6) receptor antibody, alone and in …
known as MRA), a humanized anti–interleukin‐6 (IL‐6) receptor antibody, alone and in …
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
…, P Emery, C Abud-Mendoza, J Szechinski… - Annals of internal …, 2006 - acpjournals.org
Background: The selective co-stimulation modulator abatacept demonstrated efficacy for
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …
Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind …
…, E Gromnica-Ihle, S Jeka, K Krueger, J Szechinski… - The Lancet, 2008 - thelancet.com
Background Circadian rhythms are changed in patients with rheumatoid arthritis. A new
modified-release delivery system has been developed which adapts the release of the …
modified-release delivery system has been developed which adapts the release of the …
High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti …
…, J Pazdur, J Szechinski, J Kowalczewski… - … : Official Journal of …, 2002 - Wiley Online Library
Objective To test the hypotheses that 1) proinflammatory cytokines affect osteoprotegerin (OPG)
and soluble receptor activator of nuclear factor κB ligand (sRANKL) production and …
and soluble receptor activator of nuclear factor κB ligand (sRANKL) production and …
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
F Buttgereit, D Mehta, J Kirwan, J Szechinski… - Annals of the …, 2013 - ard.bmj.com
Objective To assess the efficacy and safety of low-dose prednisone chronotherapy using a
new modified-release (MR) formulation for the treatment of rheumatoid arthritis (RA). Methods …
new modified-release (MR) formulation for the treatment of rheumatoid arthritis (RA). Methods …
Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
…, J Szechiński, T Li, J Teng… - Arthritis & …, 2008 - Wiley Online Library
Objective To evaluate the efficacy, radiographic changes, and safety of abatacept and
methotrexate therapy through 2 years in a long‐term extension of a previously published 1‐year …
methotrexate therapy through 2 years in a long‐term extension of a previously published 1‐year …
Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database
…, S Stebbings, V Stoica, A Sulli, J Szechinski… - Microvascular …, 2013 - Elsevier
Objective The aims of this study were to obtain cross-sectional data on capillaroscopy in an
international multi-center cohort of Systemic Sclerosis (SSc) and to investigate the frequency …
international multi-center cohort of Systemic Sclerosis (SSc) and to investigate the frequency …
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to …
…, P Emery, C Abud-Mendoza, J Szechinski… - Annals of the …, 2011 - ard.bmj.com
… J-CB is a full-time employee of and stockholder in Bristol-Myers Squibb. RA is a full-time
employee of and stockholder in Bristol-Myers Squibb. CP is the founder and CEO of Spire …
employee of and stockholder in Bristol-Myers Squibb. CP is the founder and CEO of Spire …